Description
Risedronic acid is a bisphosphonate clinically used to strengthen bone; it exhibits anti-osteoporotic, anti-inflammatory, antinociceptive, anti-parasitic, and antibiotic activities. Risedronic acid inhibits bone marrow adipogenesis and suppresses RANKL expression in vivo. In vivo, risedronic acid displays antimalarial activity, inhibiting the transfer of farnesyl phosphate to Plasmodium proteins and preventing parasitic growth in vivo. Additionally, risedronic acid inhibits release of TNF-α and leukotriene B4 (LTB4), decreasing inflammatory cell infiltration in vivo. In other animal models, risedronic acid inhibits chemically-induced pain.
References
Jin J, Wang L, Wang XK, et al. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res. 2013 Mar;180(1):e21-9. PMID: 22487394.
Jordão FM, Saito AY, Miguel DC, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. PMID: 21357292.
Carvalho AP, Bezerra MM, Girão VC, et al. Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice. Clin Exp Pharmacol Physiol. 2006 Jul;33(7):601-6. PMID: 16789926.
